Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.

Benyahia C, Boukais K, Gomez I, Silverstein A, Clapp L, Fabre A, Danel C, Leséche G, Longrois D, Norel X.

Prostaglandins Other Lipid Mediat. 2013 Dec;107:48-55. doi: 10.1016/j.prostaglandins.2013.07.001. Epub 2013 Jul 12.


Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.

Orie NN, Ledwozyw A, Williams DJ, Whittle BJ, Clapp LH.

Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7. doi: 10.1016/j.prostaglandins.2013.07.003. Epub 2013 Jul 18.


Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.

Benyahia C, Ozen G, Orie N, Ledwozyw A, Louedec L, Li F, Senbel AM, Silverstein A, Danel C, Longrois D, Clapp LH, Norel X, Topal G.

Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):46-52. doi: 10.1016/j.prostaglandins.2015.09.002. Epub 2015 Sep 8.


A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.

Fuchikami C, Murakami K, Tajima K, Homan J, Kosugi K, Kuramoto K, Oka M, Kuwano K.

Eur J Pharmacol. 2017 Jan 15;795:75-83. doi: 10.1016/j.ejphar.2016.11.057. Epub 2016 Dec 3.


Prostanoid receptors involved in the relaxation of human pulmonary vessels.

Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, Norel X.

Br J Pharmacol. 1999 Feb;126(4):859-66.


Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.

Whittle BJ, Silverstein AM, Mottola DM, Clapp LH.

Biochem Pharmacol. 2012 Jul 1;84(1):68-75. doi: 10.1016/j.bcp.2012.03.012. Epub 2012 Mar 27.


Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.

Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel M.

J Pharmacol Exp Ther. 2012 Dec;343(3):547-55. doi: 10.1124/jpet.112.197152. Epub 2012 Aug 23. Erratum in: J Pharmacol Exp Ther. 2013 Jan;344(1):317.


Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.

Orie NN, Clapp LH.

Eur J Pharmacol. 2011 Mar 11;654(3):258-65. doi: 10.1016/j.ejphar.2010.12.005. Epub 2010 Dec 24.


Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype.

Foudi N, Kotelevets L, Louedec L, Leséche G, Henin D, Chastre E, Norel X.

Br J Pharmacol. 2008 Aug;154(8):1631-9. doi: 10.1038/bjp.2008.214. Epub 2008 Jun 2.


Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.

Jones RL, Qian YM, Wise H, Wong HN, Lam WL, Chan HW, Yim AP, Ho JK.

J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35.


Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension.

Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, Banat GA, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT.

Am J Respir Crit Care Med. 2008 Jul 15;178(2):188-96. doi: 10.1164/rccm.200710-1519OC. Epub 2008 May 8.


Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.

Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A.

Br J Pharmacol. 1989 Jul;97(3):657-68.


Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone.

Norel X, Walch L, Gascard JP, deMontpreville V, Brink C.

Br J Pharmacol. 2004 Jun;142(4):788-96. Epub 2004 Jun 1.


Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.

Li Y, Connolly M, Nagaraj C, Tang B, Bálint Z, Popper H, Smolle-Juettner FM, Lindenmann J, Kwapiszewska G, Aaronson PI, Wohlkoenig C, Leithner K, Olschewski H, Olschewski A.

Am J Respir Cell Mol Biol. 2012 Mar;46(3):372-9. doi: 10.1165/rcmb.2010-0428OC. Epub 2011 Oct 20.


Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.

Morrison K, Ernst R, Hess P, Studer R, Clozel M.

J Pharmacol Exp Ther. 2010 Oct;335(1):249-55. doi: 10.1124/jpet.110.169748. Epub 2010 Jul 21.


Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Walch L, de Montpreville V, Brink C, Norel X.

Br J Pharmacol. 2001 Dec;134(8):1671-8.


Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.


Supplemental Content

Support Center